Нажмите на эту строку чтобы перейти к Новостям сайта "Русский врач"

Перейти
на сайт
журнала
"Врач"
Перейти на сайт журнала "Медицинская сестра"
Перейти на сайт журнала "Фармация"
Перейти на сайт журнала "Молекулярная медицина"
Перейти на сайт журнала "Вопросы биологической, медицинской и фармацевтической химии"
Журнал включен в российские и международные библиотечные и реферативные базы данных

ВАК (Россия)
РИНЦ (Россия)
Эко-Вектор (Россия)

NOVEL 6,7-DIMETHOXYQUINAZOLIN-4(3H)-ONE DERIVATIVES AS PROMISING COMPOUNDS FOR THE THERAPY OF ALZHEIMER'S DISEASE

DOI: https://doi.org/10.29296/25877313-2023-04-04
Issue: 
4
Year: 
2023

D.I. Pozdnyakov
Ph.D. (Pharm.), Head of Living System Laboratory,
Associate Professor of Department of Pharmacology with Clinical Pharmacology Course,
Pyatigorsk Medical and Pharmaceutical Institute (Pyatigorsk, Russia)
E-mail: pozdniackow.dmitry@yandex.ru
A.S. Chiryapkin
Post-graduate Student, Department of Organic Chemistry,
Pyatigorsk Medical and Pharmaceutical Institute (Pyatigorsk, Russia)
E-mail: alexey.chiriapkin@yandex.ru
I.P. Kodonidi
Dr.Sc. (Pharm.), Professor of the Department of Organic Chemistry,
Pyatigorsk Medical and Pharmaceutical Institute (Pyatigorsk, Russia)
E-mail: kodonidiip@mail.ru

Relevance. Alzheimer's disease is one of the most common forms of dementia with a high mortality and disability rate. Some quinazolinone deriva-tives having methoxy groups in the quinazolinone scaffold may be potentially effective agents for the treatment of Alzheimer's disease. The aim of the study. To evaluate the effect of new derivatives of 6,7-dimethoxyquinazoline-4(3H)-one on the activity of acetylcholinesterase and the aggregation of amyloid particles process under experimental conditions Materials and methods. The studied derivatives of 6,7-dimethoxyquinazoline-4(3H)-one with amino acid and dipeptides residues were obtained by replacing the oxygen heteroatom in the benzoxazinone core by boiling the initial compound with the corresponding amino acid. The anticholinesterase activity of the studied compounds was evaluated using an Ellman reagent with spectrophotometric detection of degradation products of 5.5'-dithiobis-2-nitrobenzoic acid. The antiamyloid activity of 6,7-dimethoxyquinazoline-4(3H)-oh derivatives was determined by a change in the intensity of aggregation of β-amyloid particles (fragment 1-42) with congo red. All tests were performed three times. Results. As a result of the study, it was found that derivatives of 6,7-dimethoxyquinazoline-4(3H)-oh inhibit the activity of acetylcholinesterase in vitro with IC50 values in the range of 1.8±0.36 mg/ml to 4.2±0.96 mg/ml, which corresponded to the indicators of the referent - donepezil (IC50 = 2.4±0.06). It is also worth noting the presence of moderate antiamyloid properties of the studied substances, which reduced the aggregation of β-amyloid parti-cles by more than 50%, which, however, was lower than the indicators of the referent - GV-791 (p

Keywords: 
quinazolinone derivatives
Alzheimer's disease
anticholinesterase agents
β-amyloid

References: 
  1. Breijyeh Z., Karaman R. Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. Molecules. 2020; 25: 5789; https://doi.org/ 10.3390/molecules25245789.
  2. Mehta R.I., Schneider J.A. What is ‘Alzheimer's disease’? The neuropathological heterogeneity of clinically defined Alzheimer's dementia. Current opinion in neurology. 2021; 34(2): 237–245; https://doi.org/10.1097/WCO.0000000000000912.
  3. Stanciu G.D., Luca A., Rusu R.N. Bild V., Beschea Chiriac S.I., Solcan C., Bild W., Ababei D.C. Alzheimer’s Disease Pharmacotherapy in Relation to Cholinergic System Involvement. Biomolecules. 2020; 10(1): 40; https://doi.org/ 10.3390/biom10010040.
  4. Hur W.S., Flick M.J. Aβ peptide and fibrinogen weave a web of destruction in cerebral amyloid angiopathy. Proceedings of the National Academy of Sciences. 2020; 117(27): 15391–15393; https://doi.org/ 10.1073/pnas.2009999117.
  5. Cortes-Canteli M., Iadecola C. Alzheimer’s disease and vascular aging: JACC focus seminar. Journal of the American College of Cardiology. 2020; 75(8): 942–951.
  6. Оганесян Э.Т., Кодониди И.П., Магонов М.М., Иванов Р.В., Кулешова С.А., Ивашев М.Н., Али Алькаф, Смирнова Л.П., Ротенко А.А. Прогноз и целенаправленный синтез n-гете-роциклических производных хиназолинона-4. Современные наукоемкие технологии. 2004; 6: 109–110 (Oganesjan Je.T., Kodonidi I.P., Magonov M.M., Ivanov R.V., Kuleshova S.A., Ivashev M.N., Ali Al'kaf, Smirnova L.P., Rotenko A.A. Prognoz i celenapravlennyj sintez n-gete-rociklicheskih proizvodnyh hinazolinona-4. Sovremennye naukoemkie tehnologii. 2004; 6: 109–110).
  7. Chiriapkin A.S., Kodonidi, I.P., Pozdnyakov D.I. Synthesis and evaluation of cerebroprotective activity of novel 6,7-dimetho-xyquinazolin-4(3H)-one derivatives containing residues of amino acids and dipeptides. Chimica Techno Acta. 2022; 9(2): 20229212; https://doi.org/10.15826/chimtech.2022.9.2.12.
  8. Chiriapkin A.S., Kodonidi I.P., Pozdnyakov D.I., Zolotych D.S. Synthesis and QSAR of new azomethine derivatives as agents for the treatment of Alzheimer's disease. Pharmacologyon-line. 2021; 3; 563–584.
  9. Chiriapkin A.S., Kodonidi I.P., Pozdnyakov D.I., Glushko A.A. Synthesis, in vitro and docking studies of 2-substituted 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine-4(3H)-one derivatives as agents for the treatment of Alzheimer's disease. Chimica Techno Acta. 2022; 9(2): 20229204; https://doi.org/10.15826/ chimtech.2022.9.2.04.
  10. Jończyk J., Godyń J., Stawarska E., Marak-Mlodawska B., Jelen M. Pluta K., Malawska B. Dual Action of Dipyridothiazine and Quinobenzothiazine Derivatives-Anticancer and Cholinesterase-Inhibiting Activity. Molecules. 2020; 25(11): 2604; https://doi.org/10.3390/molecules25112604 32.
  11. Wang W., Zhao C., Zhu D., Gong G., Du. W. Inhibition of amyloid peptide fibril formation by gold-sulfur complexes. J Inorg Biochem. 2017; 171: 1–9; https://doi.org/10.1016/j.jinorgbio. 2017.02.021.